Observational studyJournal of veterinary internal medicine2018
International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study.
Observational study in Journal of veterinary internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Cardiovascular biomarkers in feline hypertrophic cardiomyopathy phenotype: evidence from the last decade.Veterinary research communications · 2026Pooled it
- Development of an artificial intelligence-based algorithm for the detection of left atrial enlargement from feline thoracic radiographs.The veterinary quarterly · 2026Article
- Arterial Thromboembolism in a Seven-Month-Old Cat with Acute Myocardial Injury.Animals : an open access journal from MDPI · 2026Article
- First Description of Hypertrophic Cardiomyopathy Phenotype in Apparently Healthy Cats in Morocco: An Echocardiographic Prevalence Study.Animals : an open access journal from MDPI · 2026Article
- Presumed acute myocardial damage in a British Shorthair cat with previously diagnosed hypertrophic cardiomyopathy.Irish veterinary journal · 2026Article
- Efficacy of high-dose carvedilol treatment for cats with stage B1 obstructive hypertrophic cardiomyopathy.Journal of feline medicine and surgery · 2026Article
- Hypertrophic cardiomyopathy in cats: clinical prevalence, risk factors, and outcomes of arterial thromboembolism in a referral population in Tehran, Iran (2020-2024).BMC veterinary research · 2026Article
- Understanding Pathophysiological Complexity of Feline Hypertrophic Cardiomyopathy Using SWATH-MS Plasma Proteomics.Animals : an open access journal from MDPI · 2026Article
- Feline comorbidities: cardiovascular and kidney diseases.Journal of feline medicine and surgery · 2026Review
- Comparison of N-Terminal Pro-B-Type Natriuretic Peptide Between Cats with Cardiogenic Arterial Thromboembolism and Cats with Occult Cardiomyopathy Without Arterial Thromboembolism.Animals : an open access journal from MDPI · 2026Article
- Early activation of Virchow's triad in feline hypertrophic cardiomyopathy: beyond spontaneous echo contrast and insights into translational thromboembolism.Frontiers in veterinary science · 2026Review
- Patterns of morbidity, multimorbidity, and mortality in aging cats: findings from seven years of the Cat Prospective Ageing and Welfare Study.Frontiers in veterinary science · 2026Article
- Use of pimobendan in cats: a practical evidence-based review.Journal of feline medicine and surgery · 2025Review
- Feline Peritoneal Effusions-A Poor Prognosis?Animals : an open access journal from MDPI · 2025Article
- Evidence for chronic inflammation in cats with cardiomyopathies.Journal of feline medicine and surgery · 2025Article
- Unraveling the genetics of feline hypertrophic cardiomyopathy: a multiomics study of 138 cats.G3 (Bethesda, Md.) · 2025Article
- Selected Pathway Analyses to Gain Mechanistic Insights into the Pathogenesis of Feline Hypertrophic Cardiomyopathy.International journal of molecular sciences · 2025Article
- Establishing a robust genetic sequencing and gene expression data library in cardiovascularly healthy cats.Scientific reports · 2025Article
- Evolving FATE: A New Lens on the Pathogenesis and Management of Feline Cardiogenic Arterial Thromboembolism.Animals : an open access journal from MDPI · 2025Review
- Relationship Between Cardiac Troponin I Concentration and Myocardial Function in Hypertrophic Cardiomyopathy Cats With or Without Left Ventricular Outflow Tract Obstruction.Animals : an open access journal from MDPI · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
58 authors at 20 institutions in 20 countries.
Funding
Abstract
backgroundHypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. HYPOTHESIS/
objectivesObservational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). ANIMALS: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH).
methodsRetrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death.
resultsDuring the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. CONCLUSIONS AND CLINICAL IMPORTANCE: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.